



UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM
Received : 09/Mar/2024 09:57AM
Reported : 09/Mar/2024 03:10PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240062754



Page 1 of 14





Patient Name

: Mr.ASHISH UPPAL

Age/Gender

: 34 Y 6 M 2 D/M

UHID/MR No Visit ID

: SCHI.0000018704

Ref Doctor

: SCHIOPV27182 : Dr.SELF

Emp/Auth/TPA ID : FSZHDF

Collected

: 09/Mar/2024 09:12AM

Received

: 09/Mar/2024 09:57AM : 09/Mar/2024 03:10PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	16.3	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	49.80	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.67	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	87.9	fL	83-101	Calculated
MCH	28.7	pg	27-32	Calculated
MCHC	32.6	g/dL	31.5-34.5	Calculated
R.D.W	14.5	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	4,770	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUN	T (DLC)			
NEUTROPHILS	58.9	%	40-80	Electrical Impedance
LYMPHOCYTES	28.3	%	20-40	Electrical Impedance
EOSINOPHILS	3.4	%	1-6	Electrical Impedance
MONOCYTES	8.6	%	2-10	Electrical Impedance
BASOPHILS	0.8	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	2809.53	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1349.91	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	162.18	Cells/cu.mm	20-500	Calculated
MONOCYTES	410.22	Cells/cu.mm	200-1000	Calculated
BASOPHILS	38.16	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.08		0.78- 3.53	Calculated
PLATELET COUNT	260000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	04	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240062754





Patient Name : Mr.ASHISH UPPAL

Age/Gender : 34 Y 6 M 2 D/M

UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:57AM

Reported : 09/Mar/2024 03:10PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

NO HEMOPARASITES SEEN

Page 3 of 14







UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM
Received : 09/Mar/2024 09:57AM
Reported : 09/Mar/2024 03:10PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA							
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti			
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination			

Page 4 of 14







Patient Name

: Mr.ASHISH UPPAL

Age/Gender

: 34 Y 6 M 2 D/M

UHID/MR No

: SCHI.0000018704

Visit ID Ref Doctor : SCHIOPV27182 : Dr.SELF

Emp/Auth/TPA ID : FSZHDF

Collected

: 09/Mar/2024 09:12AM

Received

: 09/Mar/2024 01:54PM

Reported Status : 09/Mar/2024 02:44PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	96	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:PLF02120949

Page 5 of 14





UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 11:38AM Received : 09/Mar/2024 05:25PM

Reported : 09/Mar/2024 08:45PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	97	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 6 of 14







Patient Name : Mr.ASHISH UPPAL

Age/Gender : 34 Y 6 M 2 D/M UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 02:02PM

Reported : 09/Mar/2024 02:45PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	4.9	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	94	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Dr Nidhi Sachdev M.B.B.S, MD(Pathology) Consultant Pathologist

Dr. Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240028505

Page 7 of 14





UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:55AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 09/Mar/2024 12:17PM

DEPARTMENT OF BIOCHEMISTRY

Reported

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE , SERUM	'			
TOTAL CHOLESTEROL	179	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	133	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	62	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	117	mg/dL	<130	Calculated
LDL CHOLESTEROL	90.4	mg/dL	<100	Calculated
VLDL CHOLESTEROL	26.6	mg/dL	<30	Calculated
CHOL / HDL RATIO	2.89		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High	
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240		
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500	
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190	
HDL	≥ 60				
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220	

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 400 mg/dL. When Triglycerides are more than 400 mg/dL LDL cholesterol is a direct measurement.

Page 8 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SE04655313





Patient Name : Mr.ASHISH UPPAL

Age/Gender : 34 Y 6 M 2 D/M

UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182 Ref Doctor

Emp/Auth/TPA ID

: Dr.SELF : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:55AM

Reported : 09/Mar/2024 12:17PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
LIVER FUNCTION TEST (LFT), SERUM							
BILIRUBIN, TOTAL	1.00	mg/dL	0.20-1.20	DIAZO METHOD			
BILIRUBIN CONJUGATED (DIRECT)	0.40	mg/dL	0.0-0.3	Calculated			
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	51	U/L	<50	Visible with P-5-P			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	43.0	U/L	17-59	UV with P-5-P			
ALKALINE PHOSPHATASE	99.00	U/L	38-126	p-nitrophenyl phosphate			
PROTEIN, TOTAL	8.20	g/dL	6.3-8.2	Biuret			
ALBUMIN	4.90	g/dL	3.5 - 5	Bromocresol Green			
GLOBULIN	3.30	g/dL	2.0-3.5	Calculated			
A/G RATIO	1.48		0.9-2.0	Calculated			

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. • Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 9 of 14



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:SE04655313





Patient Name

: Mr.ASHISH UPPAL

Age/Gender

: 34 Y 6 M 2 D/M

UHID/MR No

: SCHI.0000018704

Visit ID Ref Doctor : SCHIOPV27182

Emp/Auth/TPA ID

: Dr.SELF : FSZHDF Collected

: 09/Mar/2024 09:12AM

Received

: 09/Mar/2024 02:01PM

Reported

Status

: 09/Mar/2024 02:45PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM							
CREATININE	0.86	mg/dL	0.66-1.25	Creatinine amidohydrolase			
UREA	19.40	mg/dL	19-43	Urease			
BLOOD UREA NITROGEN	9.1	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	6.28	mg/dL	3.5-8.5	Uricase			
CALCIUM	10.10	mg/dL	8.4 - 10.2	Arsenazo-III			
PHOSPHORUS, INORGANIC	2.94	mg/dL	2.5-4.5	PMA Phenol			
SODIUM	138.2	mmol/L	135-145	Direct ISE			
POTASSIUM	5.4	mmol/L	3.5-5.1	Direct ISE			
CHLORIDE	103.3	mmol/L	98 - 107	Direct ISE			
PROTEIN, TOTAL	7.99	g/dL	6.3-8.2	Biuret			
ALBUMIN	4.92	g/dL	3.5 - 5	Bromocresol Green			
GLOBULIN	3.07	g/dL	2.0-3.5	Calculated			
A/G RATIO	1.6		0.9-2.0	Calculated			

Kindly repeat with fresh sample for Potassium if clinically indicated.

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr. Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:BI18701737

Page 10 of 14







UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:55AM

Reported : 09/Mar/2024 10:31AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	30.00	U/L	15-73	Glyclyclycine Nitoranalide

Dr. SHWETA GUPTA MBBS,MD (Pathology)

SIN No:SE04655313

Consultant Pathology







UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:56AM

Reported : 09/Mar/2024 02:09PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE TOTAL (T3, T4, TS)	H), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.03	ng/mL	0.67-1.81	ELFA
THYROXINE (T4, TOTAL)	7.27	μg/dL	4.66-9.32	ELFA
THYROID STIMULATING HORMONE (TSH)	4.12	μIU/mL	0.25-5.0	ELFA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 12 of 14









Patient Name : N

: Mr.ASHISH UPPAL

Age/Gender UHID/MR No

: 34 Y 6 M 2 D/M : SCHI.0000018704

Visit ID

: SCHIOPV27182

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : FSZHDF

Collected

: 09/Mar/2024 09:12AM : 09/Mar/2024 04:55PM

Received Reported

: 09/Mar/2024 07:14PM

Status : Final Report

Sponsor Name : ARCOFE

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
COMPLETE URINE EXAMINATION (CUE) , URINE					
PHYSICAL EXAMINATION						
COLOUR	PALE YELLOW		PALE YELLOW	Visual		
TRANSPARENCY	CLEAR		CLEAR	Visual		
рН	5.0		5-7.5	Bromothymol Blue		
SP. GRAVITY	1.020		1.002-1.030	Dipstick		
BIOCHEMICAL EXAMINATION						
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR		
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD		
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING		
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE		
UROBILINOGEN	NORMAL		NORMAL	EHRLICH		
BLOOD	NEGATIVE		NEGATIVE	Dipstick		
NITRITE	NEGATIVE		NEGATIVE	Dipstick		
CENTRIFUGED SEDIMENT WET MOUNT AND MICROSCOPY						
PUS CELLS	2-3	/hpf	0-5	Microscopy		
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY		
RBC	ABSENT	/hpf	0-2	MICROSCOPY		
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY		
CRYSTALS	ABSENT		ABSENT	MICROSCOPY		

Page 13 of 14









UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 04:55PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 09/Mar/2024 07:14PM

DEPARTMENT OF CLINICAL PATHOLOGY

Reported

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick
T 4 M	B 14		D' D (D	84 41 1

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dipstick

*** End Of Report ***

Page 14 of 14







Name : Mr. ASHISH UPPAL

INDIA OP AGREEMENT

: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN

Address: DELHI

Plan

Age: 34 Y

UHID:SCHI.0000018704

Sex: M

OP Number: SCHIOPV27182

Bill No: SCHI-OCR-9727 Date : 09.03.2024 09:11

Serive Type/ServiceName Sno Department ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324 1 GAMMA GLUTAMYL TRANFERASE (GGT) 2 LIVER FUNCTION TEST (LFT) 3 GLUCOSE, FASTING 4 HEMOGRAM + PERIPHERAL SMEAR 5 DIET CONSULTATION 6 COMPLETE URINE EXAMINATION 7 URINE GLUCOSE(POST PRANDIAL) 8 PERIPHERAL SMEAR 9 ECG 10 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT) 11 DENTAL CONSULTATION La - 12-12 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL) 13 URINE GLUCOSE(FASTING) 14 HbA1c, GLYCATED HEMOGLOBIN 15 X-RAY CHEST PA 9:170 16 ENT CONSULTATION (17 CARDIAC STRESS TEST(TMT) 18 FITNESS BY GENERAL PHYSICIAN 19 BLOOD GROUP ABO AND RH FACTOR 20 LIPID PROFILE 21 BODY MASS INDEX (BMI) 23 ULTRASOUND - WHOLE ABDOMEN 24 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)

Height: A.S.C.29.

आयकर विभाग

INCOME TAX DEPARTMENT

ASHISH UPPAL

r J 3 . . .

SUBHASH CHANDER UPPAL

07/09/1989

Permanent Account Number

ABPPU6022Q

Antolon

भारत सरकार

GOVT. OF INDIA



Client Name ARCOFEMI HEALTHCARE LIMITED Patient Name Ashish uppal



NAME:	ASHISH UPPAL	AGE/SEX: 34 YRS			
UHID:	18704				
REF BY:	APOLLO SPECTRA	DATE:-	09.03.2024		

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and echotexture. Intrahepatic biliary radicles are not dilated. No focal or diffuse lesion is seen. CBD and portal vein are normal in caliber.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Prostate: normal in size, weight 21.2 Gms. It is normal in echotexture with no breech in the capsule.

No free fluid seen.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRA Consultant Radiologist

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Ashish uppal Ashish uppal Male 34Years Req. No. :	09-03-2024 HR P PR QRS QT/QTcBz P/QRS/T RV5/SV1	10:43:02 54 bpm 55 ms 148 ms 93 ms 374/388 ms 45/44/25 %	Diagnosis Information: Sinus Arrhythmia Report Confirmed by:	iation:			
	avr	<u></u> }					
	aVI				3		
3	J aVF (<u> </u>	\(\sqrt{\sq}}\sqrt{\sq}}}}}}}}\sqit{\sqrt{\sqrt{\sqrt{\sq}}}}}}}\sqrt{\sqrt{\sqrt{\sq}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}		\(\frac{1}{5}\)	<u> </u>	
	\[\frac{1}{5} \]	<u> </u>	<u> </u>	<u>}</u>	\[\frac{1}{2} \]		>
0.67-25Hz AC50 25mm/s	/s 10mm/mV 4*2:5s+1r	S+1r V2.22 SEMIP	V1.92	APOLLO SPECIALTY HOSPITALS	HOSPITALS		1 2 2 1

CERTIFICATE OF MEDICAL FITNESS

er re	viewing the medical history and on clinical examination it has been found the is
• N	Medically Fit
· H	Fit with restrictions/recommendations
n	Though following restrictions have been revealed, in my opinion, these are ot impediments to the job.
1	
2	
3	
H b	lowever the employee should follow the advice/medication that has een communicated to him/her.
R	eview after
C	urrently Unfit.
	eview afterrecommended
I	nfit

Medical Officer
The Apollo Clinic, Uppa

This certificate is not meant for medico-legal purposes

Consullation Lending

×	PI	REVENTIVE HE	ALTH CAR	E SUN	1MARV	
NAME :-	Ash			D No :	A partie	0 1
AGE / GENDER	:	34 gm	REC	EIPTA	10:-	109
PANEL:	N9	cato all	EXA	MINED	O ON : -	910
		ger, of				13
Chief Complain	nts:					
Past History:						
DM. Hypertension CAD		Nil Nil Nil	CVA Cancer Other		Nil Nil Nil	
Personal History	/:				INII	
Alcohol Smoking	:	Nil Nil	Activity Allergies		Active	
			. morgres		Nil	

Family History:

General Physical Examination:

Height 175, 4	: cms : Kgs	Pulse All m	bpm . mmHg
Rest of examination v	vas within normal limits.	120/16	mining

Systemic Examination:

CVS		
D		Normal
Respiratory system	: 1	Normal
Abdominal system		Normal
CNS	:	Normal
Others	:	Normal

PREVENTIVE HEALTH CARE SUMMARY

NAME:- Sly	UHID No:
AGE:- SEX:	RECEIPT No:-
PANEL:	EXAMINED ON : -

Investigations:

All the reports of tests and investigations are attached herewith



Recommendation:

Cap Advantage 5-4 102+1-2 monthe My Vite P3 60 Konce a week 2 maly.

Dr. Navaget Kaur Consultan PAV VALET femo = leports

Dr. Prachi Sharma 🤚

BDS, MDS - Prosthodontics and Crown & Bridge DDC No: A-14151

For Appointment: +91 11 4046 5555

Mob.:+91 9910995018

Email: drusha.maheshwari@apollospectra.com



Mr. Ashish lyppal . 34 y / Male , Regular Dentas Cherk up. c/c :-Ider Medication for Thyward, 18-9 months back, PDH: - Multiple CT Calculus &. 0/8 :-Missing next Assissed: "Scaling I tal Recophylamis

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.

No. Ashir!

Specialists in Surgery

Adu- ARC Colour Librer Eye

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.



DIGITAL X-RAY REPORT

NAME: ASHISH	DATE: 09.03.2024
UHID NO: 18704	AGE: 34YRS/ SEX: M

X-RAY CHEST PA VIEW

Both the lung fields show no active parenchymal pathology.

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab investigations

DR. MONICA CHHABRA Consultant Radiologist

Dr. MONICA CHHABRA Consultant Radic ogist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com





UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM
Received : 09/Mar/2024 09:57AM
Reported : 09/Mar/2024 03:10PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240062754



Page 1 of 14





Patient Name

: Mr.ASHISH UPPAL

Age/Gender

: 34 Y 6 M 2 D/M

UHID/MR No Visit ID

: SCHI.0000018704

Ref Doctor

: SCHIOPV27182 : Dr.SELF

Emp/Auth/TPA ID : FSZHDF

Collected

: 09/Mar/2024 09:12AM

Received

: 09/Mar/2024 09:57AM : 09/Mar/2024 03:10PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	16.3	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	49.80	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.67	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	87.9	fL	83-101	Calculated
MCH	28.7	pg	27-32	Calculated
MCHC	32.6	g/dL	31.5-34.5	Calculated
R.D.W	14.5	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	4,770	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUN	T (DLC)			
NEUTROPHILS	58.9	%	40-80	Electrical Impedance
LYMPHOCYTES	28.3	%	20-40	Electrical Impedance
EOSINOPHILS	3.4	%	1-6	Electrical Impedance
MONOCYTES	8.6	%	2-10	Electrical Impedance
BASOPHILS	0.8	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	2809.53	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1349.91	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	162.18	Cells/cu.mm	20-500	Calculated
MONOCYTES	410.22	Cells/cu.mm	200-1000	Calculated
BASOPHILS	38.16	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.08		0.78- 3.53	Calculated
PLATELET COUNT	260000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	04	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240062754





Patient Name : Mr.ASHISH UPPAL

Age/Gender : 34 Y 6 M 2 D/M

UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:57AM

Reported : 09/Mar/2024 03:10PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

NO HEMOPARASITES SEEN

Page 3 of 14







UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM
Received : 09/Mar/2024 09:57AM
Reported : 09/Mar/2024 03:10PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP ABO AND RH FACTOR	R, WHOLE BLOOD EDTA			
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 14







Patient Name

: Mr.ASHISH UPPAL

Age/Gender

: 34 Y 6 M 2 D/M

UHID/MR No

: SCHI.0000018704

Visit ID Ref Doctor : SCHIOPV27182 : Dr.SELF

Emp/Auth/TPA ID : FSZHDF

Collected

: 09/Mar/2024 09:12AM

Received

: 09/Mar/2024 01:54PM

Reported

: 09/Mar/2024 02:44PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	96	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:PLF02120949

Page 5 of 14





UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 11:38AM Received : 09/Mar/2024 05:25PM

Reported : 09/Mar/2024 08:45PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	97	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 6 of 14







Patient Name : Mr.ASHISH UPPAL

Age/Gender : 34 Y 6 M 2 D/M UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 02:02PM

Reported : 09/Mar/2024 02:45PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	4.9	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	94	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Dr Nidhi Sachdev M.B.B.S, MD(Pathology) Consultant Pathologist

Dr. Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240028505

Page 7 of 14





UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:55AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 09/Mar/2024 12:17PM

DEPARTMENT OF BIOCHEMISTRY

Reported

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE , SERUM	'			
TOTAL CHOLESTEROL	179	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	133	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	62	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	117	mg/dL	<130	Calculated
LDL CHOLESTEROL	90.4	mg/dL	<100	Calculated
VLDL CHOLESTEROL	26.6	mg/dL	<30	Calculated
CHOL / HDL RATIO	2.89		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High	
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240		
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500	
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190	
HDL	≥ 60				
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220	

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 400 mg/dL. When Triglycerides are more than 400 mg/dL LDL cholesterol is a direct measurement.

Page 8 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SE04655313





Patient Name : Mr.ASHISH UPPAL

Age/Gender : 34 Y 6 M 2 D/M

UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182 Ref Doctor

Emp/Auth/TPA ID

: Dr.SELF : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:55AM

Reported : 09/Mar/2024 12:17PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
VER FUNCTION TEST (LFT), SERUM						
BILIRUBIN, TOTAL	1.00	mg/dL	0.20-1.20	DIAZO METHOD		
BILIRUBIN CONJUGATED (DIRECT)	0.40	mg/dL	0.0-0.3	Calculated		
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength		
ALANINE AMINOTRANSFERASE (ALT/SGPT)	51	U/L	<50	Visible with P-5-P		
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	43.0	U/L	17-59	UV with P-5-P		
ALKALINE PHOSPHATASE	99.00	U/L	38-126	p-nitrophenyl phosphate		
PROTEIN, TOTAL	8.20	g/dL	6.3-8.2	Biuret		
ALBUMIN	4.90	g/dL	3.5 - 5	Bromocresol Green		
GLOBULIN	3.30	g/dL	2.0-3.5	Calculated		
A/G RATIO	1.48		0.9-2.0	Calculated		

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. • Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 9 of 14



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:SE04655313





Patient Name

: Mr.ASHISH UPPAL

Age/Gender

: 34 Y 6 M 2 D/M

UHID/MR No

: SCHI.0000018704

Visit ID Ref Doctor : SCHIOPV27182

Emp/Auth/TPA ID

: Dr.SELF : FSZHDF Collected

: 09/Mar/2024 09:12AM

Received

: 09/Mar/2024 02:01PM

Reported

Status

: 09/Mar/2024 02:45PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM						
CREATININE	0.86	mg/dL	0.66-1.25	Creatinine amidohydrolase		
UREA	19.40	mg/dL	19-43	Urease		
BLOOD UREA NITROGEN	9.1	mg/dL	8.0 - 23.0	Calculated		
URIC ACID	6.28	mg/dL	3.5-8.5	Uricase		
CALCIUM	10.10	mg/dL	8.4 - 10.2	Arsenazo-III		
PHOSPHORUS, INORGANIC	2.94	mg/dL	2.5-4.5	PMA Phenol		
SODIUM	138.2	mmol/L	135-145	Direct ISE		
POTASSIUM	5.4	mmol/L	3.5-5.1	Direct ISE		
CHLORIDE	103.3	mmol/L	98 - 107	Direct ISE		
PROTEIN, TOTAL	7.99	g/dL	6.3-8.2	Biuret		
ALBUMIN	4.92	g/dL	3.5 - 5	Bromocresol Green		
GLOBULIN	3.07	g/dL	2.0-3.5	Calculated		
A/G RATIO	1.6		0.9-2.0	Calculated		

Kindly repeat with fresh sample for Potassium if clinically indicated.

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr. Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:BI18701737

Page 10 of 14







UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:55AM

Reported : 09/Mar/2024 10:31AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	30.00	U/L	15-73	Glyclyclycine Nitoranalide

Dr. SHWETA GUPTA MBBS,MD (Pathology)

SIN No:SE04655313

Consultant Pathology







UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 09:56AM

Reported : 09/Mar/2024 02:09PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	
THYROID PROFILE TOTAL (T3, T4, TSH), SERUM					
TRI-IODOTHYRONINE (T3, TOTAL)	1.03	ng/mL	0.67-1.81	ELFA	
THYROXINE (T4, TOTAL)	7.27	μg/dL	4.66-9.32	ELFA	
THYROID STIMULATING HORMONE (TSH)	4.12	μIU/mL	0.25-5.0	ELFA	

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)		
First trimester	0.1 - 2.5		
Second trimester	0.2 - 3.0		
Third trimester	0.3 – 3.0		

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 12 of 14









Patient Name : N

: Mr.ASHISH UPPAL

Age/Gender UHID/MR No

: 34 Y 6 M 2 D/M : SCHI.0000018704

Visit ID

: SCHIOPV27182

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : FSZHDF

Collected

: 09/Mar/2024 09:12AM : 09/Mar/2024 04:55PM

Received Reported

: 09/Mar/2024 07:14PM

Status : Final Report

Sponsor Name : ARCOFE

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
COMPLETE URINE EXAMINATION (CUE) , URINE							
PHYSICAL EXAMINATION							
COLOUR	PALE YELLOW		PALE YELLOW	Visual			
TRANSPARENCY	CLEAR		CLEAR	Visual			
рН	5.0		5-7.5	Bromothymol Blue			
SP. GRAVITY	1.020		1.002-1.030	Dipstick			
BIOCHEMICAL EXAMINATION	BIOCHEMICAL EXAMINATION						
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR			
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD			
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING			
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE			
UROBILINOGEN	NORMAL		NORMAL	EHRLICH			
BLOOD	NEGATIVE		NEGATIVE	Dipstick			
NITRITE	NEGATIVE		NEGATIVE	Dipstick			
CENTRIFUGED SEDIMENT WET MOUNT AND MICROSCOPY							
PUS CELLS	2-3	/hpf	0-5	Microscopy			
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY			
RBC	ABSENT	/hpf	0-2	MICROSCOPY			
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY			
CRYSTALS	ABSENT		ABSENT	MICROSCOPY			

Page 13 of 14









UHID/MR No : SCHI.0000018704

Visit ID : SCHIOPV27182

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FSZHDF Collected : 09/Mar/2024 09:12AM Received : 09/Mar/2024 04:55PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 09/Mar/2024 07:14PM

DEPARTMENT OF CLINICAL PATHOLOGY

Reported

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick
T 4 M	B 14		D' D (D	8.8 41 1

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dipstick

*** End Of Report ***

Page 14 of 14



